FIG. 2.
Comparison between the immune responses elicited by the four different CCR5-FHV recombinant immunogens (FHV-L1, -L2, -I2, and -I3) and negative (FHV-WT) and positive (synthetic cyclic CCR589-102 peptide) controls. (A) Fractions of CCR5-binding total Igs elicited by FHV recombinant immunogens versus FHV-WT negative control. (B) CCR5 down-regulation on human CD4+ lymphocytes by purified Igs (20 ng/assay) derived from antisera elicited by FHV recombinant immunogens or FHV-WT. (C) Fractions of CCR5-binding total Igs elicited by FHV-I2, FHV-WT, and the synthetic cyclic CCR589-102 peptide administered either via systemic or mucosal route. (D) Fractions of CCR5-binding IgA and IgG purified from the total Ig fractions of panel C.